查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030年造血幹細胞移植的市場預測：按移植類型、適應症、用途、最終用戶和地區進行全球分析
市場調查報告書
商品編碼
1372011

2030年造血幹細胞移植的市場預測：按移植類型、適應症、用途、最終用戶和地區進行全球分析

Hematopoietic Stem Cell Transplantation Market Forecasts to 2030 - Global Analysis By Transplant Type, By Disease Indication, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球造血幹細胞移植（HSCT）市場規模為 28.9 億美元，預計在預測期內將以 11.3% 的年複合成長率成長，到 2030 年達到 61.2 億美元。

在稱為造血幹細胞移植（HSCT）（也稱為骨髓移植）的醫療程序中，將造血幹細胞移植到患者體內以替換或修復受損或功能障礙的骨髓。紅血球、白血球和血小板都是由造血幹細胞產生的。造血幹細胞是具有這種特殊能力的多功能細胞。

根據白血病和淋巴瘤協會（LLS）2021年發布的資料，預計2021年將有約61,090人被診斷出罹患白血病。

癌症患病增加

由於對尖端治療方案的需求，癌症罹患率的上升是造血幹細胞移植（HSCT）的主要市場促進因素。造血幹細胞移植是治療方法。隨著造血幹細胞移植的需求增加，癌症罹患率不斷增加，推動了市場的成長。這個過程涉及用受損或癌症的造血細胞替換不健康的幹細胞，並且可以治癒某些癌症。因此，癌症患者數量的增加正在推動造血幹細胞移植市場的發展，也是刺激該領域研究和開發的主要要素。

昂貴的移植手術

與整個移植手術相關的費用，包括移植前評估、移植手術本身和移植後護理，可能會令人望而卻步。對很大一部分人來說，這種經濟負擔往往限制了造血幹細胞移植作為治療選擇的可近性並影響其接受度。此外，它也為保險公司和醫療保健系統帶來了挑戰，阻礙了造血幹細胞移植的廣泛應用和採用。因此，造血幹細胞移植（HSCT）手術的高成本嚴重限制了市場。

醫療健康領域投資

隨著醫療保健產業投資的增加，造血幹細胞移植市場蘊藏著巨大的商機。許多地方政府部門也提供資金和投資來發展當地的醫療保健系統。為了支持幹細胞療法和再生醫學的研究，美國國立衛生研究院 (NIH) 於 2019 年宣布津貼2,900 萬美元。這筆津貼授予了正在利用幹細胞開發針對多種疾病的新治療方法的美國研究人員。這將使更多患者受益於這種挽救生命的治療方法，增加的投資也將支持專業移植中心的發展，改善獲得尖端護理的機會並促進創新。

造血幹細胞移植的不良反應

造血幹細胞移植市場的擴張受到阻礙，不僅因為移植物抗宿主疾病的嚴重併發症，還因為調理方案對消化器官系統、口腔、心臟和身體部位等器官和身體部位的負面影響。肺部。預計移植物抗宿主疾病（GVHD）是移植物將患者的健康細胞（宿主）誤認為是外來入侵者並對其進行攻擊和破壞的疾病。此外，即使患者和捐贈者的HLA相近，GVHD的風險也會降低，但並不能完全消除。根據具體情況，它甚至可能是致命的。預計市場將因此類事件而下跌。

COVID-19 的影響：

造血幹細胞移植 (HSCT) 市場受到 COVID-19大流行的嚴重影響。醫療保健資源的分配最初會擾亂移植計劃，並可能延遲挽救生命的治療。然而，這場危機凸顯了醫療創新和研究的重要性，可能會激發更多資金和對造血幹細胞移植作為尖端治療方法的興趣。在物流方面，供應鏈中斷減少了移植必需品的供應。遠端醫療在移植前和移植後護理中也變得普及。大流行的長期影響可能需要進行調整，以確保免疫抑制患者的安全，這可能會重塑市場。

預計自體移植領域在預測期內將是最大的。

在預測期內，造血幹細胞移植市場預計將由自體移植部門主導。自體骨髓移植涉及將從患者採集的精製骨髓進行回輸。根據國際血液和骨髓移植研究中心（CIBMTR）2020年報告，2013年美國年度異體移植受者數量超過8000例，預計2019年將有9498例移植，高於2018年的9509例。 。自2000年以來，美國自體移植患者數量穩定成長，2019年達到14,270人。在美國，超過 60% 的移植活動仍是自體移植。所有這些要素都有助於該細分市場的擴張。

骨髓移植（BMT）預計在預測期內年複合成長率

預計骨髓移植領域將在預測期內快速成長。為了取代無法產生足夠健康血球的骨髓，在骨髓移植過程中將健康的造血幹細胞注入體內。骨髓功能障礙或耗竭的患者可以透過骨髓移植獲得健康的造血幹細胞。預計該領域的成長將受到研發力度加大的推動。此外，公共和私人對骨髓移植支持的增加預計將刺激該領域的成長。

佔比最高的地區

北美造血幹細胞移植（HSCT）市場預計將佔據主要佔有率。該地區的發展主要受到白血病患者增加以及公共和私人研發投資增加等要素的推動。美國癌症研究所的資料顯示，2020年，白血病占美國新發癌症病例的3.2%，佔癌症死亡人數的3.9%。例如，2019 年 12 月，國家眼科研究所的研究人員開始進行一項臨床試驗，調查一種新型患者特異性幹細胞療法治療地圖狀萎縮的安全性。因此，白血病患者數量的增加預計將增加造血幹細胞移植的需求，從而推動該領域的市場成長。

複合年複合成長率最高的地區：

由於許多重要要素，亞太地區的造血幹細胞移植（HSCT）市場正在迅速擴張。人口老化的加劇和血液疾病的流行推動了造血幹細胞移植的需求。由於印度、中國和韓國等國家醫療保健基礎設施和醫療旅遊業的改善，該地區正在成為造血幹細胞移植的中心。此外，由於與國際醫療保健提供者和研究機構的合作，亞太地區是造血幹細胞移植服務和技術的一個充滿前景的市場。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球造血幹細胞移植（HSCT）市場：依移植類型

  • 同種異體的
  • 自體的
  • 其他類型的移植

第6章 全球造血幹細胞移植（HSCT）市場：依疾病適應症

  • 淋巴組織增生性疾病
    • 霍奇金淋巴瘤
    • 漿細胞紊亂
    • 其他淋巴組織增生性疾病
  • 非惡性疾病
    • 骨髓衰竭
    • 血紅素疾病
    • 自體免疫疾病
    • 其他非惡性疾病
  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 骨髓發育不良症候群（MDS）
    • 其他白血病
  • 其他疾病的適應症

第7章 全球造血幹細胞移植（HSCT）市場：依應用分類

  • 骨髓移植（BMT）
  • 週邊血幹細胞移植（PBSCT）
  • 臍帶血移植（CBT）
  • 其他用途

第8章 全球造血幹細胞移植 (HSCT) 市場：按最終用戶分類

  • 醫院
  • 專科診所
  • 其他最終用戶

第9章 全球造血幹細胞移植（HSCT）市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • AllCells Corp.
  • Athersys Inc.
  • Beike Biotechnology Co. Ltd.
  • bluebird bio Inc.
  • Cellular Biomedicine Group Inc.
  • Gamida Cell Ltd.
  • Lonza Group Ltd.
  • MEDIPOST Co. Ltd.
  • Merck KGaA
  • Mesoblast Ltd.
  • Pluristem Therapeutics Inc.
  • Sanofi SA
  • Sartorius CellGenix GmbH
  • ScienCell Research Laboratories, Inc.
  • STEMCELL Technologies, Inc.
  • Taiga Biotechnologies Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Talaris Therapeutics
  • Thermo Fisher Scientific
Product Code: SMRC24067

According to Stratistics MRC, the Global Hematopoietic Stem Cell Transplantation (HSCT) Market is accounted for $2.89 billion in 2023 and is expected to reach $6.12 billion by 2030 growing at a CAGR of 11.3% during the forecast period. Hematopoietic stem cells are transplanted into a patient during a medical procedure known as hematopoietic stem cell transplantation (HSCT), also referred to as bone marrow transplantation, in order to replace or repair their damaged or dysfunctional bone marrow. Red blood cells, white blood cells, and platelets can all be produced by hematopoietic stem cells, which are multipotent cells with this special ability.

According to the data published by the Leukemia & Lymphoma Society (LLS) in 2021, around 61,090 people were estimated to be diagnosed with leukemia 2021.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Due to the demand for cutting-edge treatment options, the rising incidence of cancer is a significant market driver for hematopoietic stem cell transplantation (HSCT). For patients with different types of blood cancers and hematological disorders, HSCT is an essential treatment. Cancer incidence increases along with the demand for HSCT procedures, which propels market growth. This procedure involves swapping out unhealthy stem cells for damaged or cancerous blood-forming cells, potentially curing some forms of cancer. As a result, the growing number of cancer patients is a major factor in boosting the market for HSCT and stimulating research and development in the area.

Restraint:

Expensive transplantation procedures

The costs associated with the entire transplant procedure, including pre-transplant assessments, the transplant procedure itself, and post-transplant care, can be exorbitant. For a sizeable portion of the population, this financial burden frequently restricts accessibility, which has an effect on the acceptance of HSCT as a treatment option. Additionally, it creates difficulties for insurance companies and healthcare systems, which prevents HSCT from being used and adopted more widely. As a result, the market is significantly constrained by the high cost of hematopoietic stem cell transplantation (HSCT) procedures.

Opportunity:

Investment in healthcare sector

Due to the rising investment in the healthcare industry, the hematopoietic stem cell transplantation market has a sizable opportunity. The government sector in many regions also contributes money and investments to advance the local healthcare system. In order to support research in stem cell therapy and regenerative medicine, the National Institutes of Health (NIH) announced a grant worth USD 29 million in 2019. The grant was given to US researchers that are using stem cells to create novel treatments for a number of diseases. It ensures that more patients can benefit from this life-saving therapy is created by increased investment, which also supports the development of specialized transplant centers, improves access to cutting-edge care, and fosters innovation.

Threat:

Adverse impacts of hematopoietic stem cell transplantation

The negative effects of hematopoietic stem cell transplantation on organs and body parts, including the gastrointestinal system, mouth, heart, and lungs, associated with the conditioning regimen and others, as well as the serious complication of graft vs. host disease, are anticipated to hinder the market's expansion. Both regular allogeneic stem cell transplants and reduced-intensity allogeneic stem cell transplants can result in graft-versus-host disease (GVHD), in which the graft mistakes the patient's healthy cells (the host) for foreign invaders and attacks and destroys them. Moreover, even a close HLA match between the patient and donor lowers but does not completely eliminate the risk of GVHD. It might even be fatal in some circumstances. As a result of such events, the market is expected to decline.

COVID-19 Impact:

The hematopoietic stem cell transplantation (HSCT) market was significantly impacted by the COVID-19 pandemic. Due to the allocation of healthcare resources, it initially disrupted transplant schedules, potentially delaying life-saving procedures. However, the crisis highlighted the significance of medical innovation and research, potentially spurring more funding and interest in HSCT as a cutting-edge therapy. Logistics were impacted by supply chain disruptions that reduced the supply of vital transplant supplies. Telemedicine has become more popular for pre- and post-transplant care as well. The long-term effects of the pandemic may require adjustments to ensure the safety of immunosuppressed patients, which could potentially reshape the market.

The autologous segment is expected to be the largest during the forecast period

During the anticipated period, the market for hematopoietic stem cell transplantation is anticipated to be dominated by the autologous transplantation segment. Following purification procedures, autologous bone marrow products are taken from the patient and reinfused. Allogeneic transplant recipients in the US exceeded 8,000 per year in 2013, and 9,498 transplants are anticipated in 2019, up from 9,509 in 2018, according to the Center for International Blood and Marrow Transplant Research's (CIBMTR) 2020 report. Since 2000, the number of autologous transplant recipients in the US has increased steadily, reaching 14,270 in 2019. Over 60% of transplant activity in the US still involves autologous transplants. All of these factors contribute to the segment expansion.

The bone marrow transplant (BMT) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the bone marrow transplant segment is anticipated to grow at a rapid pace. In order to replace bone marrow that does not produce enough healthy blood cells, healthy blood-forming stem cells are injected into the body during a bone marrow transplant procedure. Patients with dysfunctional or depleted bone marrow can receive healthy hematopoietic stem cells through a bone marrow transplant. Growth in the segment is anticipated to be boosted by rising research and development efforts. Additionally, it is anticipated that rising supportive actions by the public and private sectors toward bone marrow transplants will spur segment growth.

Region with largest share:

The market for hematopoietic stem cell transplantation (HSCT) in North America is expected to witness significant market share. The region is being driven primarily by factors like the rise in leukemia cases and rising public and private sector investment in research and development. Leukemia accounted for 3.2% of all new cancer cases and 3.9% of all cancer deaths in the US in 2020, according to data from the National Cancer Institute. For instance, the National Eye Institute's researchers began a clinical trial in December 2019 to examine the safety of a novel patient-specific stem cell-based therapy for the treatment of geographic atrophy. Therefore, it is anticipated that rising leukemia cases will increase demand for hematopoietic stem cell transplantation, driving up market growth in the area.

Region with highest CAGR:

Due to a number of crucial factors, the hematopoietic stem cell transplantation (HSCT) market in the Asia-Pacific region is expanding rapidly. The demand for HSCT procedures is being driven by the rising geriatric population and the prevalence of hematological disorders. The region is becoming a hub for HSCT as a result of improvements in healthcare infrastructure and medical tourism in nations like India, China, and South Korea. Furthermore, Asia Pacific is a promising market for HSCT services and technologies due to collaborations with international healthcare providers and research organizations.

Key players in the market:

Some of the key players in Hematopoietic Stem Cell Transplantation (HSCT) market include: AllCells Corp., Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular Biomedicine Group Inc., Gamida Cell Ltd., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck KGaA, Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi SA, Sartorius CellGenix GmbH, ScienCell Research Laboratories, Inc., STEMCELL Technologies, Inc., Taiga Biotechnologies Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics and Thermo Fisher Scientific.

Key Developments:

In June 2023, Kindred Group plc, a company that offers online services, launched a new campaign with Matchis, the Dutch Centre for Stem Cell Donors, to generate more awareness for stem cell transplantation and the shortage of donors.

In January 2023, Jasper Therapeutics, Inc., announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT. Previously, the U.S. Food and Drug Administration granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency (SCID).

In June 2022, Veloxis Pharmaceuticals, a specialty pharmaceutical company, announced the dosing of the first patient by its partner, Xenikos B.V., a privately held biotechnology company, in a pivotal Phase 3 clinical study [NCT04934670] designed to evaluate T-Guard versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT). T-Guard is currently being developed by Xenikos B.V.

Transplant Types Covered:

  • Allogeneic
  • Autologous
  • Other Transplant Types

Disease Indications Covered:

  • Lymphoproliferative Disorders
  • Non-malignant Disorders
  • Leukemia
  • Other Disease Indications

Applications Covered:

  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type

  • 5.1 Introduction
  • 5.2 Allogeneic
  • 5.3 Autologous
  • 5.4 Other Transplant Types

6 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Lymphoproliferative Disorders
    • 6.2.1 Hodgkin lymphoma
    • 6.2.2 Plasma Cell Disorders
    • 6.2.3 Other Lymphoproliferative Disorders
  • 6.3 Non-malignant Disorders
    • 6.3.1 Bone Marrow Failure
    • 6.3.2 Hemoglobinopathies
    • 6.3.3 Autoimmune Disease
    • 6.3.4 Others Non-malignant Disorders
  • 6.4 Leukemia
    • 6.4.1 Acute Lymphatic Leukemia
    • 6.4.2 Acute Myeloid Leukemia
    • 6.4.3 Myelodysplastic Syndrome (MDS)
    • 6.4.4 Other Leukemia
  • 6.5 Other Disease Indications

7 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application

  • 7.1 Introduction
  • 7.2 Bone Marrow Transplant (BMT)
  • 7.3 Peripheral Blood Stem Cells Transplant (PBSCT)
  • 7.4 Cord Blood Transplant (CBT)
  • 7.5 Other Applications

8 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Other End Users

9 Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AllCells Corp.
  • 11.2 Athersys Inc.
  • 11.3 Beike Biotechnology Co. Ltd.
  • 11.4 bluebird bio Inc.
  • 11.5 Cellular Biomedicine Group Inc.
  • 11.6 Gamida Cell Ltd.
  • 11.7 Lonza Group Ltd.
  • 11.8 MEDIPOST Co. Ltd.
  • 11.9 Merck KGaA
  • 11.10 Mesoblast Ltd.
  • 11.11 Pluristem Therapeutics Inc.
  • 11.12 Sanofi SA
  • 11.13 Sartorius CellGenix GmbH
  • 11.14 ScienCell Research Laboratories, Inc.
  • 11.15 STEMCELL Technologies, Inc.
  • 11.16 Taiga Biotechnologies Inc.
  • 11.17 Takeda Pharmaceutical Co. Ltd.
  • 11.18 Talaris Therapeutics
  • 11.19 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 3 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Allogeneic (2021-2030) ($MN)
  • Table 4 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Autologous (2021-2030) ($MN)
  • Table 5 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 6 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 7 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Lymphoproliferative Disorders (2021-2030) ($MN)
  • Table 8 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Hodgkin lymphoma (2021-2030) ($MN)
  • Table 9 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Plasma Cell Disorders (2021-2030) ($MN)
  • Table 10 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Lymphoproliferative Disorders (2021-2030) ($MN)
  • Table 11 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Non-malignant Disorders (2021-2030) ($MN)
  • Table 12 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Bone Marrow Failure (2021-2030) ($MN)
  • Table 13 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Hemoglobinopathies (2021-2030) ($MN)
  • Table 14 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Autoimmune Disease (2021-2030) ($MN)
  • Table 15 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Others Non-malignant Disorders (2021-2030) ($MN)
  • Table 16 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 17 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Acute Lymphatic Leukemia (2021-2030) ($MN)
  • Table 18 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Acute Myeloid Leukemia (2021-2030) ($MN)
  • Table 19 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Myelodysplastic Syndrome (MDS) (2021-2030) ($MN)
  • Table 20 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Leukemia (2021-2030) ($MN)
  • Table 21 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 22 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Bone Marrow Transplant (BMT) (2021-2030) ($MN)
  • Table 24 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Peripheral Blood Stem Cells Transplant (PBSCT) (2021-2030) ($MN)
  • Table 25 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Cord Blood Transplant (CBT) (2021-2030) ($MN)
  • Table 26 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 30 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.